<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946892</url>
  </required_header>
  <id_info>
    <org_study_id>062016-101</org_study_id>
    <nct_id>NCT02946892</nct_id>
  </id_info>
  <brief_title>Effect of Carvedilol on Exercise Performance in Fontan Patients</brief_title>
  <official_title>Effect of Carvedilol on Exercise Performance in Fontan Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of carvedilol in patients who have undergone a Fontan heart&#xD;
      operation. All participants will receive carvedilol and placebo for 12 weeks. Exercise tests&#xD;
      will be performed at the end of each 12 week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carvedilol is a well studied heart failure medication in adult heart failure that has been&#xD;
      shown to improve outcomes. However, it has not been studied in patients who have had a Fontan&#xD;
      heart operation. Study participants will receive either placebo or carvedilol for 12 weeks,&#xD;
      at the end of the 12 weeks participants will perform an exercise test. Then study&#xD;
      participants will receive treatment with placebo or carvedilol for 12 weeks (opposite of what&#xD;
      participants go the first 12 weeks) and will again perform an exercise test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake</measure>
    <time_frame>on week 12 and week 30 of the study</time_frame>
    <description>during exercise test on week 12 and week 30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Heart Rate</measure>
    <time_frame>on week 12 and week 30 of the study</time_frame>
    <description>during exercise test on week 12 and week 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen Uptake at Anaerobic Threshold</measure>
    <time_frame>on week 12 and week 30 of the study</time_frame>
    <description>during exercise test on week 12 and week 30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Single Ventricle</condition>
  <condition>Fontan</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive carvedilol for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive placebo (sugar pill) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol will be given for 12 weeks and then an exercise test will be performed</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given for 12 weeks and then an exercise test will be performed</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Carvedilol Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent of parent(s) or legal guardian; informed consent or assent of subject&#xD;
             as applicable.&#xD;
&#xD;
          2. Male or female children between the ages of 10 and 35 years with congenital heart&#xD;
             disease that has been palliated with a Fontan circulation.&#xD;
&#xD;
          3. Ability of perform a maximal exercise test as defined by a respiratory exchange ratio&#xD;
             (RER) greater than 1.0 at the time of maximal exercise&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The use of beta blockers within 2 months of randomization&#xD;
&#xD;
          2. Patients actively listed for transplantation at time of entry into the study or&#xD;
             anticipated to undergo heart transplantation, interventional catheterization, or&#xD;
             corrective cardiac surgery during the 7 months following entry into the study&#xD;
&#xD;
          3. Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the&#xD;
             use of an implantable defibrillator, and/or significant cardiac conduction defects,&#xD;
             e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning&#xD;
             pacemaker is in place&#xD;
&#xD;
          4. Uncorrected obstructive or severe regurgitant valve disease, nondilated&#xD;
             cardiomyopathy, or significant systemic ventricular outflow obstruction&#xD;
&#xD;
          5. Known renovascular hypertension or evidence of pulmonary hypertension (pulmonary&#xD;
             vascular resistance &gt; 6 Wood units) unresponsive to vasodilator agents such as oxygen,&#xD;
             nitroprusside, or nitric oxide&#xD;
&#xD;
          6. History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary&#xD;
             disease or severe reactive airway diseases (e.g., asthma) requiring hospitalization&#xD;
             within the past 2 years or patient currently using long-term inhaled bronchodilators&#xD;
&#xD;
          7. Renal, hepatic, gastrointestinal, or biliary disorder that could impair absorption,&#xD;
             metabolism or excretion of orally administered medication&#xD;
&#xD;
          8. Concurrent terminal illness or other severe disease (e.g., active neoplasm) or other&#xD;
             significant laboratory value(s) which, in the opinion of the investigator, could&#xD;
             preclude participation or survival&#xD;
&#xD;
          9. Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or&#xD;
             hypothyroidism, insulin-dependent diabetes mellitus&#xD;
&#xD;
         10. Unwillingness or inability to cooperate, or for the parents or guardians to give&#xD;
             consent, or for the child to give assent, or any condition of sufficient severity to&#xD;
             impair cooperation in the study&#xD;
&#xD;
         11. Pregnancy or possible pregnancy at time of randomization, or female of child bearing&#xD;
             potential who are lactating, or sexually active and not taking adequate contraceptive&#xD;
             precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to&#xD;
             entry into the study)&#xD;
&#xD;
         12. Use of an investigational drug within 30 days of randomization, or within 5 half-lives&#xD;
             of the investigational drug (the longer period will apply)&#xD;
&#xD;
         13. History of drug sensitivity or allergic reaction to alpha-blockers or ÃŸ-blockers&#xD;
&#xD;
         14. Use of any of the following medications within two weeks of randomization: MAO&#xD;
             inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide,&#xD;
             flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists&#xD;
&#xD;
         15. Hospital admission for protein losing enteropathy or plastic bronchitis within 3&#xD;
             months of randomization&#xD;
&#xD;
         16. Active and/or chronic protein losing enteropathy or plastic bronchitis (on inhaled&#xD;
             medication to control the plastic bronchitis).&#xD;
&#xD;
         17. Hypoalbuminemia defined as serum albumin &lt;2.0g/dL&#xD;
&#xD;
         18. Renal dysfunction defined as serum creatinine &gt;2.0mg/dL&#xD;
&#xD;
         19. Hepatic dysfunction defined as serum AST and/or ALT&gt; 3 times upper limit of normal&#xD;
             (approximately 120 IU/L however, will vary depending on age),&#xD;
&#xD;
         20. Significant anemia or polycythemia defined as hemoglobin &gt;18gm/dL or hemoglobin&#xD;
             &lt;7gm/dL&#xD;
&#xD;
         21. Severely elevated serum BNP defined as BNP&gt;300pg/ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <results_first_submitted>September 20, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ryan Butts</investigator_full_name>
    <investigator_title>ASSOC PROFESSOR, PD-Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Univentricular Heart</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02946892/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carvedilol First, Then Placebo</title>
          <description>Study participants will receive carvedilol for 12 weeks, washout for 6 weeks, then placebo for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Carvedilol</title>
          <description>Study participants will receive placebo (sugar pill) for 12 weeks, then washout for 6 weeks, then carvedilol for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Since All Participants Would Be Randomized to Both Interventions, all Patients were Analyzed</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake</title>
        <description>during exercise test on week 12 and week 30</description>
        <time_frame>on week 12 and week 30 of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carvedilol</title>
            <description>Study participants will receive carvedilol for 12 weeks&#xD;
Carvedilol: Carvedilol will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Study participants will receive placebo (sugar pill) for 12 weeks&#xD;
Placebo: Placebo will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake</title>
          <description>during exercise test on week 12 and week 30</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="3.57"/>
                    <measurement group_id="O2" value="-1.01" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Heart Rate</title>
        <description>during exercise test on week 12 and week 30</description>
        <time_frame>on week 12 and week 30 of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carvedilol</title>
            <description>Study participants will receive carvedilol for 12 weeks&#xD;
Carvedilol: Carvedilol will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Study participants will receive placebo (sugar pill) for 12 weeks&#xD;
Placebo: Placebo will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Heart Rate</title>
          <description>during exercise test on week 12 and week 30</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.3" spread="24.2"/>
                    <measurement group_id="O2" value="1.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxygen Uptake at Anaerobic Threshold</title>
        <description>during exercise test on week 12 and week 30</description>
        <time_frame>on week 12 and week 30 of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carvedilol</title>
            <description>Study participants will receive carvedilol for 12 weeks&#xD;
Carvedilol: Carvedilol will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Study participants will receive placebo (sugar pill) for 12 weeks&#xD;
Placebo: Placebo will be given for 12 weeks and then an exercise test will be performed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxygen Uptake at Anaerobic Threshold</title>
          <description>during exercise test on week 12 and week 30</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="3.75"/>
                    <measurement group_id="O2" value="-1.78" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 weeks</time_frame>
      <desc>AE were classified as serious or non-serious also related to study drug or unrelated to study drug at the time of the study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Carvedilol</title>
          <description>Study participants will receive carvedilol for 12 weeks&#xD;
Carvedilol: Carvedilol will be given for 12 weeks and then an exercise test will be performed</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Study participants will receive placebo (sugar pill) for 12 weeks&#xD;
Placebo: Placebo will be given for 12 weeks and then an exercise test will be performed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Low Heart Rate</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Butts</name_or_title>
      <organization>UTSW</organization>
      <phone>2144565822</phone>
      <email>ryan.butts@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

